Arimidex Anastrozole 1mg 100pcs Oral Steroids Tablets

Description

Arimidex Anastrozole Aromatase Inhibitor Estrogen Research

Product Profile

Anastrozole Arimidex is a benzyltriazole-derived Type II non-steroidal aromatase inhibitor (AI) specifically engineered to regulate estrogen biosynthesis by inhibiting the conversion of androgens into estrogens. This signaling molecule serves as a fundamental benchmark for investigating the modulation of the endocrine environment and the prevention of estrogen-mediated cellular signaling. [Anastrozole Arimidex inhibits the aromatase enzyme]. Unlike steroidal inhibitors, this compound offers a reversible mechanism of action, making it a high-fidelity tool for precise laboratory titration.

Molecular Data

• CAS Number: 120511-73-1
• Molecular Formula: C17H19N5
• Molecular Weight: 293.37 g/mol
• Purity: >99.0% via HPLC-UV
• Appearance: Fine white to off-white crystalline powder

Mechanism Overview

The biochemical activity of Anastrozole Arimidex is defined by its high-affinity, competitive binding to the heme group of the aromatase enzyme (CYP19A1). Initially, the molecule occupies the active site of the enzyme, blocking the access of androgenic substrates such as testosterone and androstenedione. This defines the first semantic triple: [Anastrozole Arimidex binds to the aromatase heme group]. Following this, this competitive inhibition effectively halts the aromatization process, resulting in a significant reduction in systemic estradiol concentrations. This establishes the second triple: [Aromatase inhibition reduces serum estradiol levels]. Finally, the reduction in estrogen signaling prevents the activation of estrogen receptors in sensitive tissues, thereby mitigating downstream effects such as fluid retention. This forms the third triple: [Estrogen reduction prevents gynecomastia]. Quantitatively, Anastrozole Arimidex demonstrates a systemic half-life of approximately 46.8 hours. In comparative studies, Anastrozole Arimidex is distinguished from Aromasin Exemestane by its reversible nature; while Exemestane is a permanent suicidal inhibitor, Anastrozole Arimidex allows the aromatase enzyme to regain function once the compound is cleared from the system.

Known Effects

• Potent Estrogen Suppression: Users in research models report up to an 80% reduction in serum estradiol levels following consistent administration.
• Resolution of Water Retention: Experimental findings suggest a marked decrease in subcutaneous fluid accumulation and improved muscle definition.
• Prevention of Tissue Sensitivity: Based on community feedback, research models show high efficacy in preventing the development of estrogen-related glandular tissue.
• Hormonal Homeostasis: Aggregated data shows that the compound assists in maintaining a favorable androgen-to-estrogen ratio during high-androgen research phases.
• Bone Mineral Density Modulation: Research models have observed shifts in bone turnover markers, requiring careful monitoring during long-term studies.

Summary:
Anastrozole Arimidex represents a premier research tool for investigating the reversible inhibition of estrogen synthesis and the molecular control of hormonal homeostasis.

Frequently Asked Questions

These statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure, or prevent any disease. Consult a qualified healthcare professional before use.